Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for TXMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 27.13M
March 31, 2026 26.97M
December 31, 2025 26.88M
September 30, 2025 27.44M
June 30, 2025 27.29M
March 31, 2025 26.74M
December 31, 2024 27.37M
September 30, 2024 27.09M
June 30, 2024 27.67M
March 31, 2024 28.66M
December 31, 2023 29.29M
September 30, 2023 28.05M
June 30, 2023 31.20M
March 31, 2023 32.02M
December 31, 2022
September 30, 2022 -48.27M
June 30, 2022 -26.07M
March 31, 2022 -140.58M
December 31, 2021 -93.62M
September 30, 2021 -57.36M
June 30, 2021 -49.07M
March 31, 2021 -9.478M
December 31, 2020 -124.00M
September 30, 2020 -116.03M
June 30, 2020 -94.09M
Date Value
March 31, 2020 -45.21M
December 31, 2019 9.201M
September 30, 2019 -21.23M
June 30, 2019 8.094M
March 31, 2019 60.69M
December 31, 2018 97.52M
September 30, 2018 134.22M
June 30, 2018 77.55M
March 31, 2018 107.30M
December 31, 2017 129.91M
September 30, 2017 149.48M
June 30, 2017 93.59M
March 31, 2017 110.33M
December 31, 2016 127.49M
September 30, 2016 146.35M
June 30, 2016 167.25M
March 31, 2016 183.37M
December 31, 2015 63.06M
September 30, 2015 77.56M
June 30, 2015 63.01M
March 31, 2015 87.72M
December 31, 2014 48.39M
September 30, 2014 63.60M
June 30, 2014 37.48M
March 31, 2014 46.75M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 597.21M
Corcept Therapeutics, Inc. 705.78M
Veru, Inc. 28.38M
Johnson & Johnson 84.97B
Eli Lilly & Co. 33.88B

Shareholders Equity (Quarterly) Related Metrics